Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone
Background. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass metabolism, leading to unintended adverse effects. Ca...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley
2019-01-01
|
| סדרה: | Case Reports in Infectious Diseases |
| גישה מקוונת: | http://dx.doi.org/10.1155/2019/8243868 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|